William Blair has recently reduced Maravai Lifesciences Holdings Inc (MRVI) stock to Mkt Perform rating, as announced on November 8, 2024, according to Finviz. Earlier, on August 28, 2024, Wells Fargo had initiated the stock to Overweight, setting a price target of $10. Morgan Stanley also reduced rating with a price target of $10. Additionally, Craig Hallum initiated Buy rating on April 10, 2024, with a target price of $15. BofA Securities analysts, in their report published on December 12, 2023, also raised Buy rating and set a price target of $8 for Maravai Lifesciences Holdings Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Maravai Lifesciences Holdings Inc (MRVI) Stock Trading Recap
On Friday, Maravai Lifesciences Holdings Inc (MRVI) stock saw a decline, ending the day at $5.07 which represents a decrease of $-2.77 or -35.33% from the prior close of $7.84. The stock opened at $4.75 and touched a low of $4.71 during the day, reaching a high of $5.15. The volume of shares traded was 11.40 million exceeding the average volume of 1.94 million.
Sponsored
MRVI Stock Performance and Moving Averages
In recent trading, Maravai Lifesciences Holdings Inc (MRVI) stock price has shown some volatility, fluctuating -31.97% over the last five trades and -33.49% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -51.48%, and it has plunged by -41.67% in the previous three months. Currently, MRVI is trading at -33.47%, -37.34%, and -37.47% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, MRVI, a Healthcare sector stock, is trading -56.08% below its 52-week high but remains 12.28% above its 52-week low. The Average True Range (ATR) (14 days) of 0.63 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Maravai Lifesciences Holdings Inc’s Profitability and Valuation Ratios
Maravai Lifesciences Holdings Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -15.86% and a profit margin of -81.13%, with a gross margin of -51.48%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Maravai Lifesciences Holdings Inc’s market capitalization stands at $1.28 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 4.62, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 1.64, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.53% of Maravai Lifesciences Holdings Inc (MRVI)’s shares, while financial institutions hold 88.92%.
Notable insider trades include GTCR INVESTMENT XI LLC, Director at Maravai Lifesciences Holdings Inc (MRVI), who sold 9940974 shares on May 28 ’24, at $9.81 each, totaling $97.57 million.
